Executive SummaryBaxter files PLA and ELA for the recombinant Factor VIII product for prevention and control of bleeding episodes in individuals with hemophilia A, Baxter said May 3. Recombinate was developed by Genetics Institute and is licensed to Baxter on an exclusive, worldwide basis. Last year, Genetics Institute and Genetech, which is developing a Factor VII for marketing by its licensee Miles through its Cutter Biological business, avoided a court patent battle by entering a cross-licensing arrangement for the product ("The Pink Sheet" March 27, 1989, p. 5). Baxter's Hyland Division will eventually market Recombinate.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.